Condition: Stargardt Disease-1 · Sponsor: Stargazer Pharmaceuticals, Inc.
This is an open-label, multicenter study in subjects with Stargardt disease, comparing 2 doses of STG-001 with regard to safety, pharmacokinetics and pharmacodynamics.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Associated Retina Consultants | Phoenix, Arizona, United States | — |
| Vitreo Retinal Associates, P.A. | Gainesville, Florida, United States | — |
| Casey Eye Institute - OHSU | Portland, Oregon, United States | — |
| UPMC Eye Center | Pittsburgh, Pennsylvania, United States | — |
| Retina Foundation of Southwest | Dallas, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04489511